MWVC
TEVA icon

Morgens Waterfall Vintiadis & Co’s Teva Pharmaceuticals TEVA Stock Holding History

Morgens Waterfall Vintiadis & Co’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-135,500
Closed -$7.79M – 55
2014
Q4 		$7.79M Buy
135,500
+70,500
+108% +$3.93M 4.35% 6
2014
Q3 		$3.49M Buy
+65,000
New +$3.44M 2.45% 18

Other funds holding TEVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
MIP
Mondrian Investment Partners London, United Kingdom $6.48B AUM 18.36% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
Barrow, Hanley, Mewhinney & Strauss
Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

Morgens Waterfall Vintiadis & Co's TEVA Position: Q1 2015 in Review

Morgens Waterfall Vintiadis & Co sold out of Teva Pharmaceuticals (TEVA) in Q1 2015, closing a stake of 135,500 shares — an estimated $7.79M sold.

Morgens Waterfall Vintiadis & Co first reported a position in TEVA in Q3 2014 and held it in 2 quarters. The position peaked at $7.79M in Q4 2014. 822 funds tracked by Wall St. Rank hold TEVA as of Q1 2015.

  • Morgens Waterfall Vintiadis & Co reported no remaining Teva Pharmaceuticals position as of Q1 2015 after selling out during the quarter.
  • Morgens Waterfall Vintiadis & Co sold 135,500 Teva Pharmaceuticals shares in Q1 2015, an estimated $7.79M.
  • Morgens Waterfall Vintiadis & Co first reported a position in Teva Pharmaceuticals in Q3 2014 and held it in 2 quarters.
  • Morgens Waterfall Vintiadis & Co's Teva Pharmaceuticals position peaked at $7.79M in Q4 2014.
  • 822 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2015.

Based on Morgens Waterfall Vintiadis & Co's 13F filing for Q1 2015, filed 11 May 2015.